When a patient is diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), the news lands hard. It's a rare, progressive cardiovascular disease in which misfolded proteins accumulate in the heart, steadily eroding its ability to function. For years, treatment options were limited. Then came a novel therapy with the potential to change the trajectory of the disease for patients who needed a new path forward.
Getting that therapy into the hands—and consideration—of the right patients required a smart launch. That's where Evolvics came in.